HAE

Haemonetics Corp

Add to Watchlist

Advanced Chart

75.140

+0.88(1.185%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

75.310

Open

74.400

VWAP

74.49

Vol

131.93K

Mkt Cap

3.57B

Low

73.860

Amount

9.83M

EV/EBITDA(TTM)

12.12

Total Shares

50.95M

4.50B

EV/OCF(TTM)

24.76

P/S(TTM)

2.78

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

340.59M

-2.28%

1.306

+9.72%

321.90M

-6.83%

1.172

+4.65%

304.61M

-9.39%

1.016

-0.39%

Estimates Revision

The market is revising Downward the revenue expectations for Haemonetics Corporation (HAE) for FY2026, with the revenue forecasts being adjusted by -1.25% over the past three months. During the same period, the stock price has changed by 20.20%.

Revenue Estimates for FY2026

Revise Downward

-1.25%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-0.83%

In Past 3 Month

Stock Price

Go Up

+20.20%

In Past 3 Month

7 Analyst Rating

19.20% Upside

Wall Street analysts forecast HAE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HAE is 89.57 USD with a low forecast of 71.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

19.20% Upside

Current: 75.140

Low

71.00

Averages

89.57

High

105.00

19.20% Upside

Current: 75.140

Low

71.00

Averages

89.57

High

105.00

Citi

Neutral -> Buy

upgrade

$71 -> $90

2025-07-09

Reason

Citi

Price Target

$71 -> $90

2025-07-09

upgrade

Neutral -> Buy

Reason

Citi upgraded Haemonetics to Buy from Neutral with a price target of $90, up from $71. The firm believes the company's path forward is "more derisked" following the fiscal 2026 guidance update. Haemonetics' plasma share gains are not factored into contracts, which will support high-single-digit core revenue growth and high-teens earnings growth, the analyst tells investors in a research note.

Baird

initiated

$87

2025-06-25

Reason

Baird

Price Target

$87

2025-06-25

initiated

Reason

Baird initiated coverage of Haemonetics with an Outperform rating and $87 price target.

Baird

Outperform

initiated

$87

2025-06-25

Reason

Baird

Price Target

$87

2025-06-25

initiated

Outperform

Reason

Baird initiated coverage of Haemonetics with an Outperform rating and $87 price target. As the leader in the $800M worldwide plasma collection solutions market, Haemonetics is poised to remain a beneficiary of an expanding plasma-derived therapeutics market, the analyst tells investors in a research note. Near-term, the company will contend with an anticipated plasma contract-end dragging organic growth negative-to-up low-single-digits and a revamping Vascular Closure business, but the firm sees normalized high-single and low-double digit revenue and EPS growth longer term, the firm added.

Raymond James

Strong Buy

downgrade

$115 -> $105

2025-05-09

Reason

Raymond James

Price Target

$115 -> $105

2025-05-09

downgrade

Strong Buy

Reason

Raymond James lowered the firm's price target on Haemonetics to $105 from $115 and keeps a Strong Buy rating on the shares. The Q4 print was in line on revenues and slightly ahead on EPS due to below-the-line dynamics, the analyst tells investors in a research note. The guidance for fiscal 2026 is in line to better than hopes even net of a tariff headwind and could still prove conservative, the analyst tells investors in a research note.

Needham

Mike Matson

Strong Buy

Maintains

$108 → $104

2025-03-18

Reason

Needham

Mike Matson

Price Target

$108 → $104

2025-03-18

Maintains

Strong Buy

Reason

Needham analyst Mike Matson lowered the firm's price target on Haemonetics to $104 from $108 and keeps a Buy rating on the shares. The firm is adjusting its model after the company completed the sale of its whole blood assets to GVS, S.p.A, the analyst tells investors in a research note. Needham is also cutting its FY26 EPS view by 22c to $4.99, though the firm expects Haemonetics to sustain mid- to high-single digit growth, driven by high-single digit or better non-CSL Plasma growth and mid-teens or better Hospital growth.

Barrington Research

Michael Petusky

Buy

Maintains

$108 → $95

2025-02-07

Reason

Barrington Research

Michael Petusky

Price Target

$108 → $95

2025-02-07

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Haemonetics Corp (HAE.N) is 15.32, compared to its 5-year average forward P/E of 23.31. For a more detailed relative valuation and DCF analysis to assess Haemonetics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

23.31

Current PE

15.32

Overvalued PE

31.14

Undervalued PE

15.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

14.57

Current EV/EBITDA

10.41

Overvalued EV/EBITDA

18.73

Undervalued EV/EBITDA

10.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.46

Current PS

2.72

Overvalued PS

4.53

Undervalued PS

2.40

Financials

Annual

Quarterly

FY2025Q4

YoY :

-3.70%

330.60M

Total Revenue

FY2025Q4

YoY :

+40.17%

69.85M

Operating Profit

FY2025Q4

YoY :

+184.68%

57.98M

Net Income after Tax

FY2025Q4

YoY :

+192.50%

1.17

EPS - Diluted

FY2025Q4

YoY :

+69.96%

92.45M

Free Cash Flow

FY2025Q4

YoY :

+11.49%

55.03

Gross Profit Margin - %

FY2025Q4

YoY :

+1.13%

8.92

FCF Margin - %

FY2025Q4

YoY :

+195.78%

17.54

Net Margin - %

FY2025Q4

YoY :

+25.39%

8.79

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

31.4K

Volume

Months

6-9

242.4K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

HAE News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

06:17:00

Haemonetics sees FY26 adjusted EPS $4.70-$5.00, consensus $4.93

2025-05-08

06:15:06

Haemonetics reports Q4 adjusted EPS $1.24, consensus $1.22

2025-03-06 (ET)

2025-03-06

12:45:51

Tariff delay positive for Mexico-exposed medtech companies, says BofA

News

4.0

07-09CNBC

Here are Wednesday's biggest analyst calls: Apple, Tesla, Broadcom, Meta, Wingstop, MongoDB, Caterpillar & more

6.5

06-26NASDAQ.COM

Analysts Predict 15% Gains Ahead For IJJ

9.0

06-24Newsfilter

Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe

People Also Watch

Adtalem Global Education Inc

Academy Sports and Outdoors Inc

FAQ

What is Haemonetics Corp (HAE) stock price today?

The current price of HAE is 75.14 USD — it has increased 1.19 % in the last trading day.

HAE

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

HAE News & Events

Events Timeline

News

People Also Watch

FAQ

What is Haemonetics Corp (HAE) stock price today?

What is Haemonetics Corp (HAE)'s business?

What is the price predicton of HAE Stock?

What is Haemonetics Corp (HAE)'s revenue for the last quarter?

What is Haemonetics Corp (HAE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Haemonetics Corp (HAE)'s fundamentals?

How many employees does Haemonetics Corp (HAE). have?

What is Haemonetics Corp (HAE) market cap?